Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Vascepa
Vascepa
Amarin vs. the Generics: Who Will Win?
Amarin vs. the Generics: Who Will Win?
Motley Fool
Amarin
generics
Vascepa
patents
Flag link:
AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts
AHA: Amarin's Vascepa cuts cardiovascular events in patients with coronary artery grafts
Fierce Pharma
Amarin
Vascepa
AHA
Flag link:
Amarin loses patent appeal and their brief grip on a cardiovascular, fish oil empire
Amarin loses patent appeal and their brief grip on a cardiovascular, fish oil empire
Endpoints
Amarin
Vascepa
patents
Flag link:
Amarin Patent Appeal Is a Coin Toss With Billions on the Line
Amarin Patent Appeal Is a Coin Toss With Billions on the Line
Yahoo/Bloomberg
Amarin
Vascepa
patents
Flag link:
ESC: Amarin's Vascepa reduces patients' arterial plaque after 18 months of treatment
ESC: Amarin's Vascepa reduces patients' arterial plaque after 18 months of treatment
Fierce Pharma
Amarin
Vascepa
arterial plaque
Flag link:
Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own
Amarin spurns would-be marketing partners to launch Vascepa in Europe on its own
Fierce Pharma
Amarin
Vascepa
earnings
Europe
Flag link:
Here's Why Amarin Tumbled 67.7% in the First Half of 2020
Here's Why Amarin Tumbled 67.7% in the First Half of 2020
Motley Fool
Amarin
Vascepa
Flag link:
A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success
A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success
Fierce Pharma
Amarin
Vascepa
generics
Apotex
Flag link:
FDA approves the first generic for Amarin's Vascepa — but is a launch imminent?
FDA approves the first generic for Amarin's Vascepa — but is a launch imminent?
Endpoints
FDA
Amarin
Vascepa
Hikma
generics
Flag link:
Can Amarin's Stock Recover From Its 70% Implosion?
Can Amarin's Stock Recover From Its 70% Implosion?
Motley Fool
Amarin
Vascepa
Flag link:
Are Amarin's Blockbuster Dreams Over?
Are Amarin's Blockbuster Dreams Over?
Motley Fool
Amarin
Vascepa
FDA
patents
Flag link:
Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss
Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss
Fierce Pharma
Amarin
Vascepa
generics
patents
Flag link:
Amarin aims for Vascepa boom with doubled sales force nearly in place
Amarin aims for Vascepa boom with doubled sales force nearly in place
Fierce Pharma
Amarin
Vascepa
drug reps
Flag link:
With Vascepa nod in the bag, Amarin rolls CV risk campaign targeting passé prescription meds
With Vascepa nod in the bag, Amarin rolls CV risk campaign targeting passé prescription meds
Fierce Pharma
Amarin
Vascepa
Cardiovascular
television ads
DTC ads
Flag link:
JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU
JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU
Fierce Pharma
Amarin
Vascepa
Epanova
AstraZeneca
Acasti
Europe
Flag link:
AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up
AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up
Fierce Pharma
AstraZeneca
Amarin
Vascepa
Epanova
clinical trials
Flag link:
Vascepa sparkle set to light up Amarin's fourth quarter revenue
Vascepa sparkle set to light up Amarin's fourth quarter revenue
Endpoints
Amarin
Vascepa
earnings
Flag link:
Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval
Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval
Yahoo/Marketwatch
Amarin
Vascepa
FDA
Flag link:
Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion
Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion
Fierce Pharma
Amarin
Vascepa
FDA
Cardiovascular
Flag link:
2 Top Biotech Buyout Candidates
2 Top Biotech Buyout Candidates
Motley Fool
M&A
Amarin
Vascepa
Aurinia Pharmaceuticals
voclosporin
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »